• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of bloodOriginal ArticleBlood JournalCurrent IssueAbout BloodSubmissionsSubscriptionsContact UsASH Homepage
Blood. May 15, 2007; 109(10): 4245–4248.
Prepublished online Jan 30, 2007. doi:  10.1182/blood-2006-08-039347
PMCID: PMC1885494

Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs


Mesenchymal stromal cells (MSCs) have enormous potential for the regeneration of bone, cartilage, and other tissues derived from primitive mesoderm. Despite extensive research, there is still no single marker that reliably identifies MSCs within the bone marrow. Using immunocytochemistry and flow cytometry, we demonstrate here that the neural ganglioside GD2 is expressed by MSCs either newly isolated from bone marrow or expanded in tissue culture; this finding was supported by reverse transcriptase–polymerase chain reaction (RT-PCR) analysis showing expression of the mRNA for GD2 synthase, an essential enzyme for GD2 biosynthesis. GD2 was also expressed on MSCs isolated from adipose tissue, but not on foreskin fibroblasts. Importantly, MSCs were the only cells within normal marrow that expressed this marker. Thus, GD2 appears to be the first reported single surface marker that uniquely distinguishes MSCs from other marrow elements. GD2 may prove valuable to study MSC biology and for the preparation of MSCs for clinical applications.


Human mesenchymal stromal cells (MSCs) are multipotent progenitors that can differentiate to bone, fat, cartilage, and other mesenchymal tissues.1,2 Termed mesenchymal stem cells by some investigators, MSCs can be isolated from a variety of tissues, but those from bone marrow are the most widely studied and best characterized. Interest in MSCs for diverse applications has grown rapidly over the last decade36; however, a single surface marker that would uniquely identify this population of cells within the bone marrow remains elusive.2

The first monoclonal antibodies used to characterize MSCs were SH2 and SH3,7 which later were shown to recognize epitopes on CD1058 and CD73,9 respectively. While these antigens remain the cornerstone of human MSC identification,2 they are also expressed on hematopoietic and endothelial cells. GD2 is a disialoganglioside found mainly in the nervous system. Reports of neural antigen expression on MSCs10,11 led us to consider that these cells might express GD2, which could be a useful marker of MSCs, as its expression should not extend to hematopoietic cells or other normal marrow elements. Here, we demonstrate the expression of GD2 by MSCs but not other cells within the bone marrow, suggesting that this antigen might serve as a single definitive marker of marrow-derived MSCs.

Materials and methods

Isolation of human MSCs

Bone marrow MSCs (from multiple donors) were isolated according to a protocol approved by the institutional review board of St Jude Children's Research Hospital, Memphis, TN, as previously described.12 Adipose-derived MSCs were obtained from tissue generously provided by Dr Jeffrey Gimble according to a standard protocol described elsewhere.13


We performed immunocytochemical studies on a formalin-fixed cell culture expanded on a sterile chamber slide, using a murine monoclonal antibody against GD2 (clone 14.G2A; BD Biosciences, San Jose, CA). The reaction was visualized with a biotinylated goat antimouse secondary antibody with ABC substrate and Nova Red as the chromogen (Vector Labs, Burlingame, CA). All slides were lightly counterstained with hematoxylin. Stained slides were examined on an Olympus BX41 (Olympus America, Melville, NY) with a 4×/0.13 NA dry objective, and photomicrographs were acquired using the attached SPOT RT color camera and SPOT RT v 3.2 software (Diagnostic Instruments, Sterling Heights, MI). Images were cropped and labeled using Photoshop 7.0 and Illustrator 10.0 (Adobe Systems, San Jose, CA).

Reverse transcription PCR

RNA was extracted with Trizol Reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). Primers for GD2 synthase were forward 5′-CCAACTCAACAGGCAACTAC-3′, reverse 5′-GATCATAACGGAGGAAGGTC-3′ (230-bp product), and forward 5′-GACAAGCCAGAGCGCGTTA-3′, reverse 5′-TACTTGAGACACGGCCAGGTT-3′ (99-bp product); primers for β2-microglobulin (333-bp product) were forward 5′-CTCGCGCTACTCTCTCTTTCTTGG-3′, reverse 5′-GCTTACATGTCTCGATCCACTTAA-3′. Polymerase chain reaction (PCR) conditions were denaturation at 95°C for 12 minutes, then 35 cycles at 95°C for 1 minute, 59°C for 1 minute, 72°C for 1 minute, and then 72°C for 10 minutes.

MSC differentiation

Culture-expanded MSCs were differentiated in vitro to osteoblasts,14 adipocytes,15 and chondroblasts,16 as described. The differentiated osteoblasts were stained with Alizarin Red S,17 the adipocytes with Oil Red O,18 and the chondroblasts with Alcian Blue,19 according to published protocols. Stained differentiated cells were imaged on a Nikon Eclipse TE300 inverted microscope (Nikon, Melville, NY) with a 40×/0.6 NA objective and an attached Nikon D70 camera (Nikon). Images were cropped and labeled using Photoshop 7.0 and Illustrator 10.0 (Adobe Systems).

Flow cytometry

All analyses were performed on a BD LSR II flow cytometer (BD Biosciences, San Jose, CA), with antibodies from BD Biosciences, except that the monoclonal antibody against human fibroblasts, clone D7-FIB, was from Serotec (Raleigh, NC). The data were analyzed with Cell Quest Pro Software Version 5.2.1 (BD Biosciences).

Immunoselection of MSCs

GD2-expressing MSCs were isolated from freshly harvested bone marrow mononuclear cells using our murine monoclonal antibody against GD2 and an allophycocyanin-conjugated donkey antimouse secondary antibody with the corresponding magnetic beads on an AutoMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany), according to the manufacturer's instructions.

Results and discussion

Human MSCs isolated from bone marrow showed the characteristic features of spindle shape and plastic adherence (Figure 1Ai). Flow cytometric analysis demonstrated the expression of distinguishing MSC antigens (CD105, CD73, and CD90), and the absence of hematopoietic and endothelial antigens (CD45, CD34, CD19, CD3, CD11b, and HLA DR; Figure 1Aii). The culture-expanded cells were capable of in vitro differentiation to osteoblasts as demonstrated by Alizarin Red staining; adipocytes, as demonstrated by Oil Red O staining; and chondroblasts as demonstrated by Alcian Blue staining (Figure 1Aiii-v). Thus, the isolated cells met the essential criteria used to define MSCs.2

Figure 1
GD2 expression on marrow MSCs. (Ai) Photomicrograph of undifferentiated MSCs showing the characteristic spindle shape and adherent properties of the cells. Original magnification, ×40. (ii) Flow cytometry histograms demonstrating the typical expression ...

Immunocytochemical staining of the marrow-derived MSCs revealed striking expression of the neural ganglioside GD2 (Figure 1Bi). Comparable staining was found on all MSCs, indicating a pancellular expression of GD2 among these bone marrow elements. Staining of MSCs without the primary antibody yielded negative results, demonstrating the lack of nonspecific staining (Figure 1Bii). To assess GD2 expression by an alternative method, we analyzed culture-expanded cells by flow cytometry, finding high levels of GD2 surface expression (Figure 1Biii). Reverse-transcription PCR analysis using 2 different primer pairs, with a neuroblastoma cell line and blood mononuclear cells serving as positive and negative controls, respectively, showed that MSCs expressed the mRNA for GD2 synthase (Figure 1Biv), an essential enzyme for GD2 biosynthesis. These results provide crucial supportive evidence of genuine ganglioside expression on MSCs.

All cells analyzed in the preceding experiments had been expanded for 2 passages in culture. Since GD2 can play a role in cellular adhesion20 we considered that plastic adherence of MSCs in vitro might induce or alter the expression of GD2 in a manner different from the normal regulation of the ganglioside. To address this possibility, we analyzed newly harvested bone marrow mononuclear cells (MNCs) by 4-color flow cytometry, gating first on marrow MNCs that lacked CD45 expression (Figure 1Ci, gate R1). These cells (R1) were then analyzed for CD105 and CD73 expression (Figure 1Cii). About 95% of the CD45CD105+ CD73+ cells (gate R2) expressed GD2 (Figure 1Ciii). Further, newly harvested marrow MNCs that expressed either CD271 or D7Fib, both of which have been suggested to represent MSCs,21,22 were found to coexpress GD2 (data not shown). The intensity of GD2 expression exceeded that of either CD271, which is lost during culture, or D7Fib, which is also expressed on skin fibroblasts. Notably, the entire population of expanded MSCs continued to express GD2 at similar levels through 8 culture passages (Figure 1D).

To determine if GD2 expression is unique to marrow-derived MSCs, we analyzed such cells from adipose tissue. As shown in Figure 1E, the adipose-derived cells also expressed GD2 at approximately the same level as marrow-derived MSCs. Foreskin fibroblasts, by contrast, lacked GD2 expression (Figure 1E).

Finally, flow cytometric analysis of unfractionated marrow cells, leukocytes (CD45), hematopoietic progenitors (CD34), myeloid cells (CD33), T-lymphocytes (CD3), and B-lymphocytes (CD19) demonstrated the absence of GD2 expression (Figure 1F). Our RNA analysis revealed the lack of GD2 synthase expression in circulating blood cells (Figure 1B). Most importantly, immunohistochemical staining of normal bone marrow biopsy specimens (Figure 1F) did not detect other GD2-expressing cells. Collectively, these data indicate the lack of hematopoietic GD2 expression, consistent with prior reports.23,24

Cells isolated from freshly harvested bone marrow by selection for GD2 expression using immunomagnetic beads demonstrated typical MSC morphology and plastic adherence (Figure 2). The culture-expanded cells differentiated to osteoblasts, adipocytes, and chondroblasts (Figure 2), as expected for MSCs.

Figure 2
Ex vivo expansion and trilineage differentiation of GD2-selected MSCs. Photomicrograph of undifferentiated, ex vivo–expanded cells (upper panel) after isolation by GD2 selection. The characteristic spindle shape morphology and plastic adherence ...

GD2 is the first candidate marker of MSCs to be consistently expressed at a high level on all cells of this population, whether freshly isolated or ex vivo expanded; hence, GD2 selection may offer an improved approach for MSC identification and isolation. Immune recognition of the GD2-expressing MSCs in the marrow microenvironment may underlie the hematopoietic suppression observed when anti-GD2 antibodies are used as immunotherapy for neuroblastoma.

A critical question in MSC biology is whether this cell population possesses a relatively uniform differentiation capability, and responds to specific signals to generate diverse mesenchymal lineages, or is comprised of biologically distinct subsets of progenitors committed to differentiate in particular pathways. The availability of a marker antigen such as GD2 would be useful in resolving this issue, much in the way that CD34 has helped to discriminate among subsets of hematopoietic progenitors.


The authors gratefully acknowledge Drs Richard Ashmun, Ann Marie Hamilton-Easton, and James Houston for the flow cytometric analyses, and John Gilbert for editorial review. This work was supported in part by grants NHLBI R01 HL077 643 and NCI T32 CA070 089, Cancer Center Support (CORE) grant NCI P30 CA 21 765, and the American Lebanese Syrian Associated Charities (ALSAC).


The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.


Contribution: C.M. designed, performed, and analyzed research, and assisted with preparation of the manuscript; T.J.H. designed and analyzed research; R.M. provided important analytical tools and performed research; M.D. provided important analytical tools and analyzed research; E.M.H. supervised the entire project, designed and analyzed research, and prepared the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Edwin M. Horwitz, Division of Bone Marrow Transplantation, St Jude Children's Research Hospital, 332 N Lauderdale, Mail Stop 321, Memphis, TN 38105; e-mail: gro.edujts@ztiwroh.niwde.


1. Horwitz E, Le BK, Dominici M, et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393–395. [PubMed]
2. Dominici M, Le BK, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317. [PubMed]
3. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441. [PubMed]
4. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96:1593–1603. [PubMed]
5. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002;99:8932–8937. [PMC free article] [PubMed]
6. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309–313. [PubMed]
7. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–650. [PubMed]
8. Barry FP, Boynton RE, Haynesworth S, Murphy JM, Zaia J. The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun. 1999;265:134–139. [PubMed]
9. Barry F, Boynton R, Murphy M, Zaia J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Comm. 2001;289:519–524. [PubMed]
10. Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells. 2006;24:1054–1064. [PubMed]
11. Padovan CS, Jahn K, Birnbaum T, et al. Expression of neuronal markers in differentiated marrow stromal cells and CD133+ stem-like cells. Cell Transplant. 2003;12:839–848. [PubMed]
12. Marx JC, Allay JA, Persons DA, et al. High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells. Hum Gene Ther. 1999;10:1163–1173. [PubMed]
13. Mitchell JB, McIntosh K, Zvonic S, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells. 2006;24:376–385. [PubMed]
14. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol. 1994;161:218–228. [PubMed]
15. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res. 1998;13:371–382. [PubMed]
16. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res. 1998;238:265–272. [PubMed]
17. Bodine P, Trailsmith M, Komm B. Development and characterization of a conditionally transformed adult human osteoblastic cell line. J Bone Miner Res. 1996;11:806–819. [PubMed]
18. Sekiya I, Larson BL, Vuoristo JT, Cui JG, Prockop DJ. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res. 2004;19:256–264. [PubMed]
19. Wang Y, Belflower RM, Dong YF, et al. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J Bone Miner Res. 2005;20:1624–1636. [PubMed]
20. Jabbar AA, Kazarian T, Hakobyan N, Valentino LA. Gangliosides promote platelet adhesion and facilitate neuroblastoma cell adhesion under dynamic conditions simulating blood flow. Pediatr Blood Cancer. 2006;46:292–299. [PubMed]
21. Jones EA, Kinsey SE, English A, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum. 2002;46:3349–3360. [PubMed]
22. Jones EA, English A, Henshaw K, et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum. 2004;50:817–827. [PubMed]
23. Moss TJ, Reynolds CP, Sather HN, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. 1991;324:219–226. [PubMed]
24. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res. 2001;7:1698–1705. [PubMed]

Articles from Blood are provided here courtesy of American Society of Hematology
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...